Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02429570 · ClinicalTrials.gov registry record · NA
Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
A NA study of Recurrent Brain Metastases and Progressive Brain Metastases, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT02429570: Active NA study of Recurrent Brain Metastases and Progressive Brain Metastases, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02429570 is a NA study of Recurrent Brain Metastases and Progressive Brain Metastases that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02429570, a NA study of Recurrent Brain Metastases and Progressive Brain Metastases, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasis. This is the first time that meclofenamate will be used in patients with brain metastasis. This is a pilot study which means that the purpose of this study is to determine if a larger clinical trial of meclofenamate is possible in patients with brain metastasis. This study also aims to find out what effects, good and/or bad meclofenamate has on the patient and the cancer that has spread to the brain. The investigators also want to learn more about potential effects that this drug may have in the digestive system.
Primary Outcome
The trial will be deemed "feasible" if at least 50% of patients enrolled are evaluable in brain by MRI at the 2-month timepoint.
Conditions Studied
Interventions
- DRUG Meclofenamate
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center at Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Florida
- Baptist Health South Florida - Miami
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04-22 |
| Est. Completion | 2027-04 |
| Phase | NA |
What the registry record for NCT02429570 still lists
NCT02429570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Recurrent Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which Meclofenamate is the first listed.
NCT02429570 lists 7 locations in 4 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT02429570 about?
NCT02429570 is a clinical study titled "Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary". Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasi...
What is the current status of trial NCT02429570?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2015-04-22. Estimated completion is 2027-04.
What conditions does trial NCT02429570 study?
This clinical trial studies the following conditions: Recurrent Brain Metastases, Progressive Brain Metastases.
What interventions are being tested in trial NCT02429570?
The interventions under investigation include: Meclofenamate (DRUG).
Who is sponsoring clinical trial NCT02429570?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02429570 being conducted?
This trial has 7 study locations across Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02429570's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI